CL2007003514A1 - Compuestos derivados de quinolina; procedimiento de preparacion de dichos compuestos; combinacion farmaceutica; y uso de los compuestos para preparar un medicamento para tratar una infeccion bacteriana. - Google Patents

Compuestos derivados de quinolina; procedimiento de preparacion de dichos compuestos; combinacion farmaceutica; y uso de los compuestos para preparar un medicamento para tratar una infeccion bacteriana.

Info

Publication number
CL2007003514A1
CL2007003514A1 CL200703514A CL2007003514A CL2007003514A1 CL 2007003514 A1 CL2007003514 A1 CL 2007003514A1 CL 200703514 A CL200703514 A CL 200703514A CL 2007003514 A CL2007003514 A CL 2007003514A CL 2007003514 A1 CL2007003514 A1 CL 2007003514A1
Authority
CL
Chile
Prior art keywords
compounds
quinolina
prepare
procedure
preparation
Prior art date
Application number
CL200703514A
Other languages
English (en)
Spanish (es)
Inventor
Jerome Emile George Guillemont
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38126091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003514(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2007003514A1 publication Critical patent/CL2007003514A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CL200703514A 2006-12-06 2007-12-05 Compuestos derivados de quinolina; procedimiento de preparacion de dichos compuestos; combinacion farmaceutica; y uso de los compuestos para preparar un medicamento para tratar una infeccion bacteriana. CL2007003514A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06125499 2006-12-06

Publications (1)

Publication Number Publication Date
CL2007003514A1 true CL2007003514A1 (es) 2008-07-11

Family

ID=38126091

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703514A CL2007003514A1 (es) 2006-12-06 2007-12-05 Compuestos derivados de quinolina; procedimiento de preparacion de dichos compuestos; combinacion farmaceutica; y uso de los compuestos para preparar un medicamento para tratar una infeccion bacteriana.

Country Status (32)

Country Link
US (1) US8415475B2 (cg-RX-API-DMAC7.html)
EP (1) EP2099758B1 (cg-RX-API-DMAC7.html)
JP (1) JP5466011B2 (cg-RX-API-DMAC7.html)
KR (1) KR101490222B1 (cg-RX-API-DMAC7.html)
CN (2) CN101553470A (cg-RX-API-DMAC7.html)
AP (1) AP2479A (cg-RX-API-DMAC7.html)
AR (1) AR064151A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007328887B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0720220B8 (cg-RX-API-DMAC7.html)
CA (1) CA2669819C (cg-RX-API-DMAC7.html)
CL (1) CL2007003514A1 (cg-RX-API-DMAC7.html)
CY (1) CY1117766T1 (cg-RX-API-DMAC7.html)
DK (1) DK2099758T3 (cg-RX-API-DMAC7.html)
EA (1) EA016733B1 (cg-RX-API-DMAC7.html)
ES (1) ES2573689T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160585T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028769T2 (cg-RX-API-DMAC7.html)
IL (1) IL199083A (cg-RX-API-DMAC7.html)
JO (1) JO3271B1 (cg-RX-API-DMAC7.html)
ME (1) ME02498B (cg-RX-API-DMAC7.html)
MX (1) MX2009005978A (cg-RX-API-DMAC7.html)
MY (1) MY181645A (cg-RX-API-DMAC7.html)
NO (1) NO341983B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ576823A (cg-RX-API-DMAC7.html)
PL (1) PL2099758T3 (cg-RX-API-DMAC7.html)
PT (1) PT2099758E (cg-RX-API-DMAC7.html)
RS (1) RS54794B1 (cg-RX-API-DMAC7.html)
SI (1) SI2099758T1 (cg-RX-API-DMAC7.html)
TW (1) TWI406659B (cg-RX-API-DMAC7.html)
UA (1) UA100972C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008068267A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200903950B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358506B (es) 2012-04-27 2018-08-22 Janssen Pharmaceutica Nv Derivados de quinolina antibacterianos.
EP2841425B1 (en) 2012-04-27 2016-03-23 Janssen Pharmaceutica, N.V. Antibacterial quinoline derivatives
BR112015008515A2 (pt) 2012-10-16 2017-07-04 Janssen Pharmaceutica Nv moduladores de ror t de quinolinila ligada à heteroarila
ES2628365T3 (es) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
PE20150778A1 (es) 2012-10-16 2015-05-23 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de ror-gamma-t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
WO2015057626A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv QUINOLINYL MODULATORS OF RORyT
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
EP3170810B1 (en) * 2014-07-14 2018-09-19 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
UA126891C2 (uk) * 2015-01-27 2023-02-22 Янссен Фармацевтика Нв Здатні до диспергування композиції
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN105601566A (zh) * 2016-02-02 2016-05-25 张敏 一种护理烧伤后感染的药物组合物
ES2934785T3 (es) 2016-03-07 2023-02-27 Global Alliance For Tb Drug Development Inc Compuestos antibacterianos y usos de los mismos
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
US20210052597A1 (en) * 2018-01-29 2021-02-25 Cadila Healthcare Limited Heterocyclic compounds useful as antibacterial agents
IL302095A (en) * 2020-10-22 2023-06-01 Lunella Biotech Inc Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270123A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
JP4484703B2 (ja) * 2002-07-25 2010-06-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用
PL1711181T3 (pl) 2004-01-23 2010-02-26 Janssen Pharmaceutica Nv Pochodne chinoliny i ich zastosowanie jako inhibitorów mykobakteryjnych
US7338949B2 (en) 2004-01-23 2008-03-04 Janssen Pharmaceutica N.V. Mycobacterial inhibitors
EA011572B9 (ru) 2004-01-29 2018-01-31 Янссен Фармацевтика Н.В. Производные хинолина для применения в качестве микобактериальных ингибиторов
AU2005249231B2 (en) * 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
PT1797115T (pt) 2004-09-28 2017-08-29 Janssen Pharmaceutica Nv Domínio de ligação de atp-sintase bacteriana
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
CN104744361A (zh) 2015-07-01
PT2099758E (pt) 2016-06-02
MY181645A (en) 2020-12-30
NZ576823A (en) 2012-01-12
CN104744361B (zh) 2021-06-08
BRPI0720220A2 (pt) 2013-12-24
EA200970535A1 (ru) 2009-10-30
CN101553470A (zh) 2009-10-07
HRP20160585T1 (hr) 2016-06-17
HUE028769T2 (en) 2017-01-30
PL2099758T3 (pl) 2016-08-31
RS54794B1 (sr) 2016-10-31
JO3271B1 (ar) 2018-09-16
EA016733B1 (ru) 2012-07-30
UA100972C2 (ru) 2013-02-25
BRPI0720220B1 (pt) 2020-06-09
SI2099758T1 (sl) 2016-07-29
AP2009004874A0 (en) 2009-06-30
BRPI0720220B8 (pt) 2021-05-25
WO2008068267A1 (en) 2008-06-12
CA2669819A1 (en) 2008-06-12
EP2099758B1 (en) 2016-03-09
IL199083A (en) 2014-08-31
DK2099758T3 (en) 2016-06-13
NO341983B1 (no) 2018-03-05
HK1208437A1 (en) 2016-03-04
KR101490222B1 (ko) 2015-02-05
AP2479A (en) 2012-09-27
ES2573689T3 (es) 2016-06-09
CY1117766T1 (el) 2017-05-17
US20100048566A1 (en) 2010-02-25
CA2669819C (en) 2016-08-30
KR20090086604A (ko) 2009-08-13
ME02498B (me) 2017-02-20
NO20092542L (no) 2009-08-25
JP2010511668A (ja) 2010-04-15
EP2099758A1 (en) 2009-09-16
TWI406659B (zh) 2013-09-01
AR064151A1 (es) 2009-03-18
AU2007328887B2 (en) 2013-01-17
TW200838528A (en) 2008-10-01
IL199083A0 (en) 2010-03-28
JP5466011B2 (ja) 2014-04-09
ZA200903950B (en) 2010-08-25
US8415475B2 (en) 2013-04-09
AU2007328887A1 (en) 2008-06-12
MX2009005978A (es) 2009-06-16

Similar Documents

Publication Publication Date Title
CL2007003514A1 (es) Compuestos derivados de quinolina; procedimiento de preparacion de dichos compuestos; combinacion farmaceutica; y uso de los compuestos para preparar un medicamento para tratar una infeccion bacteriana.
CL2008001002A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CL2008001003A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CL2007003685A1 (es) Compuestos derivados de indol con un anillo unido en las posiciones 4 y 5; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion viral.
CL2007003684A1 (es) Compuestos derivados de indol con un anillo unido en las posiciones 5 y 6; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion viral.
CL2008001367A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion bacteriana.
CL2007003645A1 (es) Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria.
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
CL2008000496A1 (es) Compuestos derivados de purina; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades infecciosas, cancer, alergias y otras afecciones inflamatorias.
CL2007002446A1 (es) Compuestos derivados de morfolino pirimidina; composicion farmaceutica; y su uso para preparar un medicamento para producir un efecto antiproliferante.
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
CL2014000732A1 (es) Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende.
IL212435A (en) Isoindulin compounds, their pharmaceutical compositions and their use in the preparation of drugs
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
CL2012003632A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidinas o una sal farmaceuticamente aceptable de los mismos; composicion farmaceutica que los comprende; y su uso para tratar una infeccion por virus pneumovirinae o una infeccion por virus sincicial respiratorio.
BRPI1013394A2 (pt) "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
CL2007002284A1 (es) Compuestos derivados de tetrazolilos macrociclicos; proceso de preparacion; composicion farmaceutica; y uso para tratar una infeccion viral de hepatitis c.
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
UY30759A1 (es) Compuestos quimicos
BRPI0812738A2 (pt) Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
BRPI1006040A2 (pt) uso de composições farmacêuticas, tipo de curativo médico, e, tipo de caixa de medicamento
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
WO2011012322A3 (en) Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."